Vektor Medical, Inc. was founded by a close-knit team of engineers, scientists, doctors, and entrepreneurs with the shared belief that harnessing the power of computational modeling could vastly improve cardiac arrhythmia care.
Our mission is to deliver an innovative, non-invasive arrhythmia mapping solution that’s capable of helping physicians provide personalized solutions for the treatment of complex cardiac rhythm disorders. We aim to accomplish this through superior leadership, cutting-edge technology, ongoing physician education and outreach, and patient service.
Mike Monko is a recognized senior executive with over 20 years of leadership and management experience in the life science, biotech, and diagnostics industries. Prior to his leadership at Vektor, Mike served as an executive at Life Technologies, Serologicals, and Sequenom.
For nearly two decades, Rob Krummen has served in a variety of roles, leading and advising corporations, nonprofits, institutions of higher education, and state entities. Rob is a former partner at Vorys, Sater, Seymour and Pease LLP and a former Deputy Solicitor General for the State of Ohio. He had the privilege of clerking for the Honorable R. Guy Cole of the United States Court of Appeals for the Sixth Circuit. Rob earned his JD from Harvard Law School.
Dr. Christopher Villongco has over a decade of experience in computational modeling and high-performance computing. He conducted doctoral and post-doctoral research in the Departments of Bioengineering and Medicine at the University of California, San Diego. His work focused on developing and applying patient-specific computational models of cardiac electrophysiology to solve real-world clinical problems, especially heart failure and arrhythmias.
Doug has over 25 years of executive-level finance, technology, risk management, and investment experience spanning more than 20 different industries. He was a founding partner in one of the first electronic derivative trading firms, a director and member of the Investment and Risk Committee, taught futures and options theory, has been a small business mentor, a CEO Coach, and has served on several boards in various roles, including managing a multi-asset class P.E. fund.
Kalle Marsal is a senior executive, board member, investor, and advisor to many successful ventures and non-profit organizations across several life-science and high-technology sectors. He served as COO for a Nasdaq-listed mid-cap company, is a former management consultant at Bain & Company, and is a former senior executive at HP. He earned his MBA and MS at Stanford University.
Emily Lovell brings over a decade of marketing and PR experience to the Vektor team. Prior to joining Vektor, Emily worked for Etsy.com, leading strategic communications for the then relatively unknown start-up, through IPO and beyond. She is passionate about building and driving awareness for emerging businesses and has a wealth of experience developing and executing impactful, transparent, and informative campaigns.
Dr. David Krummen is a professor of medicine at the University of California San Diego and the director of electrophysiology at the VA San Diego Healthcare System. He is a recognized expert in cardiac arrhythmia research. He pioneered ventricular fibrillation electrical substrate ablation, and has authored more than 80 papers in the field.
Dr. Andrew McCulloch is Distinguished Professor of Bioengineering and Medicine at UC San Diego and Director of the Institute of Engineering in Medicine. His laboratory has pioneered the use of multi-scale computational modeling both for elucidating the molecular mechanisms of heart disease and for patient-specific diagnosis and therapy planning in the clinical management of cardiac arrhythmias, heart failure, and congenital heart diseases.
Dr. Gordon Ho is an assistant professor of medicine at the University of California San Diego. He has more than 10 years of experience in computational modeling, ventricular fibrillation, and atrial fibrillation. Dr. Ho was recently awarded National Institutes of Health and American Heart Association career development grants to study the mechanisms of atrial fibrillation.